Company intelligence / Profile preview
Solid Biosciences
- Ownership
- Public · SLDB
- Development stage
- Other
01
Overview
Solid Biosciences is advancing multiple programs across neuromuscular and cardiac diseases, with SGT-003 for Duchenne muscular dystrophy in Phase I/II clinical trials.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Gene TherapyGenetic Medicines
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
Mayo Clinic
04
Financials
- Market cap
- $662.7M
- Total revenue
- $0
- Enterprise value
- $333.3M
Beyond the preview
Go deeper on Solid Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solid Biosciences.